Navigation Links
Spectral appoints Anthony Bihl to Board of Directors
Date:3/6/2008

TORONTO, March 6 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. (TSX:SDI) today announced that Mr. Anthony Bihl has been appointed to the Company's Board of Directors.

"As the former CEO of Siemens Medical Solutions Diagnostics, a combination of the former Bayer Diagnostics and Diagnostic Products Corporation, Mr. Bihl will be a valuable addition to our Board," said Dr. Paul Walker, President and CEO of Spectral Diagnostics. "Mr. Bihl is a 25 year veteran in the field of diagnostics and is well-suited to advise Spectral on our global commercialization strategy of the EAA(TM) Endotoxin Activity Assay, the only FDA cleared diagnostic for the measurement of endotoxin."

Mr. Bihl has more than 25 years of experience with diagnostic products, having held leadership roles in global healthcare businesses, including a broad base of operational and executive positions in large and medium multinational healthcare firms. Before his role as CEO of Siemens Medical Solutions Diagnostics, Mr. Bihl served in senior leadership roles at Bayer Healthcare Diagnostics, having held the roles of Senior VP of Finance and Administration and President, responsible for all aspects of this worldwide business Division. Prior to his tenure at Bayer, Mr. Bihl gained extensive operational experience through more than 20 years at E.I. DuPont Inc. His final role at DuPont was as Plant Manager for medical instrument manufacturing.

Mr. Bihl received a Bachelor's Degree in Business Administration from Pennsylvania State University, and is a member of the Board of Directors for Adnavance Technologies Inc.

About Spectral Diagnostics

Spectral is a developer of innovative technologies for comprehensive disease management. Spectral's lead product is its EAA(TM) Endotoxin Activity Assay, the only FDA approved diagnostic for the measurement of endotoxin. Spectral technologies provide accurate and timely information to clinicians enabling the early initiation of appropriate and targeted therapy. Spectral is listed on TSX under the symbol SDI.

Forward-looking statement

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.

The TSX has not reviewed and does not accept responsibility for the

adequacy or accuracy of this statement.


'/>"/>
SOURCE Spectral Diagnostics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Spectral announces data on the clinical utility of EAA(TM) to be presented at 12th Annual Critical Care for Endotoxemia Conference in Japan
2. CRi Announces Nuance 2, the Next-Generation Multispectral Imaging System for Brightfield and Fluorescent-Based Microscopy
3. US Patent and Trademark Office Allows CRis Patent Application for Spectral Imaging of Deep Tissue
4. Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany
5. Tianyin Pharmaceutical Appoints Three New Independent Board Members
6. Hiemstra Appoints Robert C. Glines as Director of Business Development
7. Tengion Appoints Jeff Randall to Board of Directors
8. Ambrx Appoints Douglas Axelrod Senior Vice President for Clinical Research and Development
9. BioStorage Technologies Appoints Dr. Wolfgang Hoffer as Managing Director of European Operations
10. Stem Cell Company t2cure Appoints Dr Rueck Head of Clinical Operations
11. Human Genome Sciences Appoints Maxine Gowen, Ph.D., to Its Board Of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Regular discussions on a range of subjects ... the two entities said Poloz. Speaking at a ... , he pointed to the country,s inflation target, which ... "In certain areas ... have common economic goals, why not sit down and address ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS ... the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, ... proud to add Target to its list of well-respected retailers. This list includes ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
(Date:6/23/2016)... ... 23, 2016 , ... STACS DNA Inc., the sample tracking software company, today ... Laboratory, has joined STACS DNA as a Field Application Specialist. , “I am ... and COO of STACS DNA. “In further expanding our capacity as a scientific integrator, ...
Breaking Biology Technology:
(Date:5/16/2016)... 16, 2016   EyeLock LLC , a market ... opening of an IoT Center of Excellence in ... the development of embedded iris biometric applications. ... convenience and security with unmatched biometric accuracy, making it ... from DNA. EyeLock,s platform uses video technology to deliver ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
Breaking Biology News(10 mins):